Literature DB >> 10875486

Demographic characteristics of patients experiencing near-fatal and fatal asthma: results of a regional survey of 400 asthma specialists [see comment].

P J Hannaway1.   

Abstract

BACKGROUND: Case-control studies now describe a growing number of younger patients with varying levels of asthma severity who experience near-fatal or fatal asthma unexpectedly at home, en route to the hospital, or in public places.
OBJECTIVE: To collect case reports and analyze the demographic characteristics and patient profiles that may help identify predisposing factors which trigger near-fatal and fatal asthma episodes.
METHODS: In order to gather case reports and analyze the demographics and clinical characteristics of patients experiencing near-fatal and fatal asthma, a questionnaire on near-fatal and fatal asthma was distributed to 400 regional asthma specialists.
RESULTS: Forty physicians reported 25 cases of near-fatal asthma and 20 cases of fatal asthma. Twenty-five patients (13 males and 12 females) with a mean age of 29.4 years experienced near-fatal asthma. The time of onset of the near-fatal event was sudden (less than 3 hours) in 60% of cases and 76% of the episodes occurred at home or en route to the hospital. All 25 patients were using short acting inhaled beta agonists and 88% were reportedly using inhaled corticosteroids on a daily basis. Good to excellent compliance was noted in 60% of patients. Six patients were using a peak flow meter prior to their near-fatal attack. Predisposing psychosocial factors for life threatening asthma were noted in 44% of patients. Twenty patients, (4 males and 16 females) with a mean age of 21.7 years experienced fatal asthma. The time of onset of the fatal event was sudden (less than 3 hours) in 80% of cases and all but one patient died at home, en route to the hospital, or in a public place. All 20 patients were using short acting inhaled beta agonists, 80% were reportedly on daily inhaled corticosteroids and six patients were on oral corticosteroids. Good to excellent compliance was noted in 60% of patients. Only two patients were using a peak flow meter immediately prior to their fatal attack. Predisposing psychosocial factors for life threatening asthma were noted in 45% of decedent patients. Risk factors for fatal asthma included running in cold weather, over relying on home nebulizers, and a delay in seeking care on long holiday weekends.
CONCLUSIONS: While approximately 50% of the patients in this survey had moderate to severe asthma tainted by adverse psychosocial factors, nearly half of near-fatal and fatal attacks occurred suddenly and unexpectedly, outside the hospital in stable, younger, atopic, reportedly compliant patients utilizing inhaled corticosteroids on a daily basis. This regional survey supports the need for additional studies and the establishment of a national case registry to collect case reports and analyze the demographics and clinical characteristics of patients experiencing near-fatal and fatal asthma in order to further define the risk factors and develop preventative protocols for patients at risk for near-fatal or fatal asthma.

Entities:  

Mesh:

Year:  2000        PMID: 10875486     DOI: 10.1016/s1081-1206(10)62408-8

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  2 in total

1.  Effectiveness of nebulizer use-targeted asthma education on underserved children with asthma.

Authors:  Arlene M Butz; Mona G Tsoukleris; Michele Donithan; Van Doren Hsu; Ilene Zuckerman; Kim Elizabeth Mudd; Richard E Thompson; Cindy Rand; Mary Elizabeth Bollinger
Journal:  Arch Pediatr Adolesc Med       Date:  2006-06

2.  A Randomized, Double-Blind, Placebo-Controlled Trial of Escitalopram in Patients with Asthma and Major Depressive Disorder.

Authors:  E Sherwood Brown; Nasreen Sayed; Erin Van Enkevort; Alexandra Kulikova; Alyson Nakamura; David A Khan; Elena I Ivleva; Prabha Sunderajan; Bruce G Bender; Traci Holmes
Journal:  J Allergy Clin Immunol Pract       Date:  2018-03-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.